Research Reports
Interoperability of data to accelerate the US Animal Drug Compounding Market
Published On :
The US Animal Drug Compounding Market is likely to scintillate going forward. With various cloud options to explore, the healthcare industry is expected to be at a newer high in the forecast period. In other words, organizations across the globe are advancing their downtime regarding digital business initiatives. They are swiftly moving towards the cloud for modernizing the environments, enhancing system reliability, supporting hybrid work models, and addressing the other new-fangled realities surfacing in recent times. This would be the outlook of the healthcare vertical in the upcoming period.
Persistence Market Research published a report on the animal drug compounding market, which considers the U.S. industry analysis 2014 – 2018 and opportunity assessment 2019 – 2029, and projects that the animal drug compounding market is expected to reach ~ US$ 1 Bn by the end of 2019 in terms of value, and is forecasted to reach ~ US$ 2 Bn by the end of 2029.
Want Insights To US Animal Drug Compounding Market? Ask For Sample! https://www.persistencemarketresearch.com/samples/30058
Company Profiles:
- Hoye’s Pharmacy
- Vertisis Custom Pharmacy
- Smith Caldwell Drug Store
- Sixth Avenue Medical Pharmacy
- Dougherty’s Pharmacy
- Triangle Compounding Pharmacy Inc.
- Medisca Inc.
- Wedgewood Pharmacy
- Millers Pharmacy
Planning To Conclude Your Strategy On A Decisive Note In The US Animal Drug Compounding Market? Glance Through The “Methodology” Implied! https://www.persistencemarketresearch.com/methodology/30058
Availability of Alternative Dosage Forms Boosting the Demand for Animal Drug Compounding
Commercially available veterinary drugs often come in a single dosage or strength. Animal drug compounding is able to produce desired drugs with alternate dosage and varied dosage forms, which is not possible during the production of branded drugs. Such types of animal drug compounding involve concentrating the drug in the flavoured gel that is generally applied to the paw or fur of the animal, and is administered by licking. Also, dosage forms such as transdermal drug delivery in animals, are widely accepted in diverse range of animal drug compounding. To cite an example, anti-parasitic drugs for cattle and anti-flea drugs for dogs and cats are most successful transdermal drug delivery transdermal compounded drug products.
Lower Availability of Generic Substitutes for Veterinary Drugs
Availability of generic substitutes is much lower for veterinary drugs. Most drugs available for animals for critical diseases are branded drugs. Additionally, currently there is no reimbursement available for veterinary drugs, which indicates that most of the drug expense goes out of the pockets of animal owners. In such circumstances, most pet owners prefer resorting to animal drug compounding that are easily available, cheaper than branded equivalents, and do not require multiple prescriptions.
CNS Drugs to be Most Frequently Dispensed Extemporaneous Medications from Animal Drug Compounding Pharmacies
Central nervous system inflammation is the most common cause of neurological disorders in dogs and cats. Abnormal limb coordination, seizures, behavioral changes, and blindness are cited as the most common abnormalities in dogs and cats with central nervous system inflammation. For instance, according to the International Journal of Pharmaceutical Compounding, central nervous system drugs were the most commonly dispensed medications from animal drug compounding pharmacies with approximately 39% of the total veterinary prescriptions.
Absence of Adverse Event Reporting in Animal Drug Compounding
Individual boards of animal drug compounding pharmacies of various states in the U.S. haven’t reported any incidences of adverse events related to animal drug compounding. Furthermore, the U.S. FDA’s adverse drug event reporting system for animals is also not aggregated or comprehensive, and is currently being revised. Since 2001, only 62 compound-related adverse events in animal drug compounding have been reported to the FDA. No definitive trends can be derived out of them. Therefore, absence of adverse event reporting in animal drug compounding will upsurge the demand for animal drug compounding pharmacies.
How About Knowing The Product/Technology Driving The US Animal Drug Compounding Market Before Investing Therein? Click The “Purchase Now” Button Of Our US Animal Drug Compounding Market Report! https://www.persistencemarketresearch.com/checkout/30058
Unsafe Compounding Practices May Deter the Growth of Animal Drug Compounding
The primary factor restraining the usage of animal drug compounding is unsafe compounding practices, which include compounding contaminations and non-adherence to GMP regulations. This is very prominent across sterile compounding involving injectable drugs and intravenous solutions. Contaminated sterile environments lead to spread of pathogens and fungal infections, and have resulted in various hazards and drug-related deaths, thus dampening the prospects for animal drug compounding. To avoid unsafe animal drug compounding practices, the U.S. FDA has made it mandatory for all outsourcing facilities manufacturing bulk drugs to be inspected and to secure cGMP certification.
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.
-
-
BUSINESS2 days ago
UK pay growth weakest since February 2021, REC survey show
-
-
-
NEWS2 days ago
ECB will probably cut rates in Oct on risk of too low inflation: Villeroy
-
-
-
NEWS2 days ago
Japan leads Asia stock rally, dollar firms after blowout US payrolls
-
-
-
NEWS2 days ago
Adani Group in talks to buy Heidelberg’s Indian cement operations, paper says
-